The official logo of Nigh Goldenberg Raso & Vaughn, PLLC, featuring the law firm's name in stylized typography with a professional color scheme.

The Ozempic Lawsuit: What it Could Mean for Rybelsus, Wegovy and Trulicity

The Ozempic Lawsuit, officially known as MDL 3094 IN RE: GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONISTS (GLP-1 RAS) PRODUCTS LIABILITY LITIGATION, was formed on February 2, 2024 in the Eastern District of Pennsylvania. The Judge assigned to the litigation is Judge Gene E. K. Pratter. The lawsuit alleges that the manufacturers failed to warn consumers about the potential risks associated with the use of Ozempic, Wegovy, and other drugs that belong to the glucagon-like peptide-1 receptor agonists (GLP-1 RA) class and share the same active ingredient: semaglutide.

This article focuses on the potential inclusion of other GLP-1 RA manufacturers such as Rybelsus and Trulicity in the Ozempic class action lawsuit, and the implications it could have for patients and healthcare providers. The FDA’s addition of intestinal blockage/obstruction and ileus to Ozempic’s warning label in September 2023 may also play a role in the development of this case.

Overview of the Ozempic Lawsuit

The Ozempic lawsuit, officially known as MDL 3094 IN RE: GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONISTS (GLP-1 RAS) PRODUCTS LIABILITY LITIGATION, has consolidated at least 55 lawsuits against Novo Nordisk and Eli Lilly in the Eastern District of Pennsylvania. The multidistrict litigation (MDL) streamlines legal proceedings for cases related to Ozempic, Wegovy, Saxenda, Trulicity, and Rybelsus, with the potential to include up to 10,000 cases. Plaintiffs allege severe gastrointestinal side effects and failure to warn users about potential risks, while the pharmaceutical companies deny any liability or wrongdoing.

Key developments in the Ozempic lawsuit include:

  • In 2023, the American Diabetes Association (ADA) and individual plaintiffs filed a lawsuit against Novo Nordisk, alleging deceptive marketing practices, misrepresentation of benefits, and downplaying risks.
  • The FDA added ileus to Ozempic’s label as a gastrointestinal disorder associated with adverse reactions during postmarketing experience.
  • As of February 2024, the lawsuits reached a milestone with the formation of a multidistrict litigation (MDL), consolidated under a single federal judge in Philadelphia.
  • Legal experts anticipate the number of lawsuits to increase in 2024 due to growing awareness among patients and healthcare professionals about potential side effects.

Eligibility for filing an Ozempic lawsuit includes proof of treatment, a diagnosis of an adverse health condition, and a related emergency room visit, hospitalization, or visit with a gastroenterologist. Compensation in these lawsuits can cover medical treatment costs, lost income, pain and suffering, loss of enjoyment of life, loss of earning capacity, and possible punitive damages. How much each plaintiff’s Ozempic claim is worth depends on factors such as the severity of injuries or damages, the cost of medical treatment, impact on quality of life, lost wages, and emotional distress. The value of damages will vary from case to case.

Potential Inclusion of Other Manufacturers

The Ozempic lawsuit, while initially focused on Novo Nordisk and Eli Lilly, may expand to include other manufacturers of GLP-1 receptor agonists. Individuals who qualify for a potential claim or inclusion in the MDL typically share experiences of being prescribed these drugs for diabetes management or weight loss and suffering severe gastrointestinal issues.

The team at Nigh Goldenberg Raso and Vaughn is now accepting cases involving:

  • Gastroparesis: A condition where the stomach cannot empty food properly, leading to nausea, vomiting, and severe abdominal bleeding.
  • Intestinal Obstruction (Ileus): A potentially life-threatening condition where the intestine is blocked, inhibiting the passage of food and fluids.

The team at Nigh Goldenberg Raso & Vaughn is diligently working to secure justice for those who have suffered from medical complications related to their Ozempic use. If you or a loved one has experienced any of the above-mentioned complications, please contact us today.

The manufacturers of Ozempic, Novo Nordisk, and Eli Lilly, are accused of failing to warn about these risks. As the lawsuit progresses, it is likely that other manufacturers of similar GLP-1 receptor agonists, such as those behind Rybelsus, Wegovy, and Trulicity, may be included in the class action if their products are found to have similar side effects and risks that were not adequately disclosed to patients and healthcare providers.

Implications for Patients and Healthcare Providers

The Ozempic lawsuit has significant implications for patients and healthcare providers, emphasizing the importance of transparent communication between pharmaceutical companies and consumers. Lawyers are investigating Ozempic lawsuits for patients with gastrointestinal conditions, including gastroparesis or cyclic vomiting syndrome

The first Ozempic stomach paralysis lawsuit was filed on Aug. 2, 2023. The lawsuits claim that Ozempic can cause severe gastroparesis, ileus, and intestinal blockages. The plaintiffs in these lawsuits have developed severe gastroparesis, ileus, or intestinal obstruction after taking Ozempic. They are seeking compensation for loss of quality of life, past and future medical bills, and other damages.

Key implications for patients and healthcare providers include:

  • Increased awareness of potential side effects and risks associated with Ozempic and similar GLP-1 receptor agonists
  • Need for thorough patient education and informed consent before prescribing these medications
  • Importance of monitoring patients for gastrointestinal complications and promptly addressing any concerns
  • Potential changes in prescribing practices and treatment guidelines based on the outcome of the lawsuit
  • Heightened scrutiny of pharmaceutical companies’ marketing practices and disclosure of risks

Future Developments and Legal Industry Impact

On Feb. 2, 2024, a federal panel combined at least 55 lawsuits into a multidistrict litigation, with all federal Ozempic lawsuits consolidated before Judge Pratter in the Eastern District of Pennsylvania. The first status conference in the Ozempic lawsuit was held on March 14, 2024. During this conference, The Judge asked for proposals from the lawyers on each side about how they would organize the case, set schedules, and handle requests for documents from the drug manufacturers. The Court also scheduled a ‘science day’. This is a hearing where each side will present to The Judge about the science behind the litigation. 

The experienced lawyers at Nigh Goldenberg Raso and Vaughn, PLLC are currently accepting Ozempic cases. Founding Partner, Daniel Nigh, Esq., has been proposed as a member of the executive committee for the litigation. If this position is approved by The Court, he will be working extensively on the litigation. 

The legal industry should anticipate the following developments:

  1. A surge in lawsuits as more patients come forward with claims of gastrointestinal injuries caused by Ozempic.
  2. The outcome of the Ozempic lawsuit could set a precedent for future cases involving similar medications, potentially influencing the regulatory environment and pharmaceutical companies’ approaches to drug safety.
  3. Heightened public scrutiny and media attention surrounding the Ozempic lawsuit, which could impact public perception of the industry and the pharmaceutical companies involved.

If you or a loved one has suffered from these injuries, we encourage you to contact us for a free consultation. Our skilled team is ready to listen to your story, evaluate your case, and discuss the best course of action moving forward. Remember, you are not alone in this fight, and with our help, we can seek justice together.


Q: Is there an ongoing legal case against Ozempic? A: Yes, a lawsuit has been initiated against Ozempic due to severe gastroparesis symptoms experienced by plaintiffs. The suit, filed on August 2, 2023, accuses Eli Lilly and Co. of not adequately warning users about the potential risks.

Q: What potential compensation can be expected from an Ozempic lawsuit? A: The value of each plaintiff’s Ozempic claim is determined by several factors, including the severity of the injuries or damages, the expenses related to medical treatment, the impact on their quality of life, any lost wages, and the emotional distress experienced. It’s important to note that the value of damages will differ from case to case, as each individual’s circumstances are unique. Therefore, it’s essential to consult with our legal experts who can assess the specifics of your situation and provide personalized guidance.

Q: Are there any legal actions against Rybelsus? A: Yes, Novo Nordisk, the maker of Rybelsus, along with Ozempic and Wegovy, is facing several lawsuits. These federal lawsuits have been consolidated into a multidistrict litigation (MDL) in the Eastern District of Pennsylvania.

Q: Have there been any fatalities associated with Ozempic? A: A study from October 2022 examined 5,442 adverse gastrointestinal events linked to the drug class including Ozempic. This study reported 40 deaths, 53 life-threatening incidents, and 772 hospitalizations.

Free Consultation

Fill out the form below or call Nigh Goldenberg Raso & Vaughn today for a free consultation 202-792-7927

Skip to content